ProMedix

Executive Summary

ProMedix Inc. is a San Diego-based medical technology company developing the PeriFRL, a noninvasive digital sensor for rapid, objective measurement of capillary refill time (CRT) to detect worsening peripheral blood flow. Current CRT assessment is manual and subjective, leading to delayed recognition of circulatory dysfunction in critical care. The PeriFRL aims to replace this with a standardized, real-time metric, potentially improving outcomes in sepsis, shock, and perioperative monitoring. The device is in development, targeting FDA clearance and initial commercialization. ProMedix operates at the intersection of diagnostics and digital health, with a focus on reducing time-to-intervention in hospital settings. If successful, the PeriFRL could become a standard vital sign in acute care, addressing a significant unmet need for early detection of hemodynamic instability.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for PeriFRL40% success
• Q3 2026Publication of Pivotal Clinical Study Results50% success
• Q2 2026Strategic Partnership with Hospital Network or Distributor35% success